{"filings":[{"id":1416356,"accession_number":"0001493152-26-031930","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-07-02T20:40:47+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics posts updated investor presentation; no specific details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation posted on July 2, 2026, replacing the February 26, 2026 version.","Presentation available on company website from July 3, 2026.","No financial or operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1415957,"accession_number":"0001493152-26-031920","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-07-02T20:30:32+00:00","items":["5.07","9.01"],"status":"ready","headline":"Ernexa Therapeutics shareholders elect directors, ratify auditor, approve 2026 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Bristol, Cicala, Luther, Ratner, Wexler; broker non-votes 161,165.","Ratification of Haskell & White LLP as auditor for FY 2026: 590,236 for, 29,010 against, 495 abstentions.","Approval of 2026 Omnibus Equity Incentive Plan: 363,640 for, 94,840 against, 96 abstentions, 161,165 broker non-votes.","Quorum of 53.13% (619,741 of 1,166,333 shares) represented at the July 1, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1304879,"accession_number":"0001493152-26-030306","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-06-26T20:30:19+00:00","items":["5.02","9.01"],"status":"ready","headline":"SVP of Finance Sandra Gurrola resigns, effective July 3, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Gurrola, SVP of Finance, resigned June 22, 2026, effective July 3, 2026.","Resignation not due to any disagreement with the Company's operations, policies, or practices.","Gurrola will provide part-time transition assistance (up to 10 hrs/week) through Q2 2026 10-Q filing.","Company has initiated search for a successor and will use outside support for finance, accounting, and reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98661,"accession_number":"0001493152-26-021112","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ernexa Therapeutics effects 1-for-25 reverse stock split, effective May 4, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio; trading on split-adjusted basis began at market open on May 4, 2026.","Certificate of Amendment filed with Delaware Secretary of State on May 1, 2026.","New CUSIP number for common stock post-split: 114082407.","Common stock (ERNA) and warrants (ERNAW) trade on Nasdaq under split-adjusted terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114268,"accession_number":"0001493152-26-011922","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ernexa Therapeutics receives Nasdaq delisting bid-price notice; ineligible for cure due to prior reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.","Company not eligible for standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) due to reverse stock split within past year.","Intends to request hearing before Nasdaq Hearing Panel; request stays suspension/delisting pending panel decision and possible 180-day extension.","No assurance that panel will grant extension or that securities (ERNA, ERNAW) will remain listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114267,"accession_number":"0001493152-26-008182","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics posts updated investor presentation on February 26, 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation replaces the December 11, 2025 version; available on company website.","Presentation furnished under Item 7.01 Regulation FD; no financial statements or material agreements attached.","Specific content of the update is not disclosed in the filing; investors should review the presentation directly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114266,"accession_number":"0001493152-26-006227","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics prices $10.5M public offering of 21M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 21M shares of common stock (or equivalents) and warrants to buy 21M shares at $0.50 per unit.","Gross proceeds expected ~$10.5M; net proceeds for development programs, working capital, and general purposes.","Warrants exercisable at $0.68/share, expire 5 years from issuance or 180 days after release of Phase 1 ERNA-101 data.","Brookline Capital Markets acted as exclusive placement agent; offering closed Feb 10, 2026.","Potential additional $14.3M if all warrants exercised on cash basis (no assurance given)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130643,"accession_number":"0001493152-25-027167","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics posts new investor presentation; details not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made a December 2025 investor presentation available via 8-K and its website.","No financial or operational data from the presentation is included in the filing.","Investors will need to access the company website to view the presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147189,"accession_number":"0001641172-25-018009","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ernexa Therapeutics dismisses Grant Thornton, appoints Haskell & White as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissal of Grant Thornton effective June 30, 2025; appointment of Haskell & White effective July 1, 2025, approved by Audit Committee.","Grant Thornton's reports for FY 2023 and 2024 included a going-concern explanatory paragraph but were otherwise unqualified.","No disagreements with Grant Thornton; only disclosed material weakness in FY 2023 internal controls from lack of technical accounting proficiency.","Grant Thornton provided a letter to the SEC regarding the dismissal, attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165799,"accession_number":"0001641172-25-014877","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ernexa Therapeutics effects 1-for-15 reverse stock split effective June 12, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of amendment filed with Delaware Secretary of State on June 10, 2025.","Reverse stock split ratio is 1-for-15.","Effective date of reverse stock split is June 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165798,"accession_number":"0001641172-25-014318","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Ernexa completes second closing of $6M private placement; total $7M raised; expects to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing on June 9, 2025: issued 47.7M shares and 9.3M pre-funded warrants for ~$6.0M gross proceeds.","Combined with April 2 closing, total 57.7M shares and 9.8M warrants issued for ~$7.0M.","Proceeds to be used for working capital and repaying certain notes.","Company believes it now satisfies Nasdaq Stockholders' Equity Standard ($2.5M minimum) as alternative to Market Value Standard.","Pre-funded warrants exercisable at $0.005 per share with 4.99%/9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165797,"accession_number":"0001641172-25-013249","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.","Approved amendment to increase authorized common stock from 100M to 150M shares.","Approved reverse stock split at Board's discretion within 1-for-10 to 1-for-15 ratio.","Approved stockholder action by written consent, removing meeting-only requirement.","Ratified Grant Thornton as auditor for 2025 and approved potential issuance >20% under March 31 securities purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165800,"accession_number":"0001641172-25-002514","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","3.02","5.08","9.01"],"status":"ready","headline":"Eterna Therapeutics raises up to $7.3M in private placement; resets annual meeting to June 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing on April 2: sold 9.93M shares and 509,736 pre-funded warrants for $1.1M.","Second closing of $6.2M (48.33M shares, 10.54M warrants) subject to stockholder approval by June 30 (or July 30 if SEC reviews).","Purchase price $0.1046 per share; pre-funded warrants at $0.0996 with $0.005 exercise price.","Investors include existing 32% holder Charles Cherington and former director Nicholas Singer.","2025 annual meeting moved to June 2; stockholder proposal deadline is April 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183362,"accession_number":"0001641172-25-000681","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Eterna Therapeutics renames to Ernexa Therapeutics Inc. effective March 26, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed its name from Eterna Therapeutics Inc. to Ernexa Therapeutics Inc.","Filed Certificate of Amendment to Restated Certificate of Incorporation with Delaware Secretary of State.","Adopted amended and restated bylaws solely to reflect the name change.","Effective date of name change: March 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183361,"accession_number":"0001641172-25-000300","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Eterna Therapeutics issues $750K promissory note to insider Charles Cherington at 5% due June 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750,000 promissory note to Charles Cherington, who owns ~32% of ERNA shares.","Note bears 5% annual interest, payable at maturity; default rate 7%.","Matures on earliest of June 15, 2025, or when Eterna raises >$5M in equity/convertible debt.","Cherington also holds a $1.5M note from March 11, 2025, making total insider debt $2.25M.","Note includes customary events of default, cross-default >$50k, and bankruptcy clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183360,"accession_number":"0001493152-25-010049","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Eterna Therapeutics issues $1.5M promissory note to Charles Cherington at 5%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $1,500,000 at 5.0% annual interest, paid at maturity.","Matures June 15, 2025, or earlier if Eterna raises >$5M in equity or convertible debt.","Default rate set at 7.0% per annum on overdue amounts.","Proceeds received on March 11, 2025; loan can be prepaid without penalty.","Cross-default triggered if Eterna fails to pay >$50K in other debt after grace period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183359,"accession_number":"0001493152-25-006446","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Eterna Therapeutics sets 2025 annual meeting for May 1; shareholder proposals due Feb 23","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting date: May 1, 2025; over 30 days before one-year anniversary of 2024 meeting.","Stockholder proposals and director nominations must be received by Feb 23, 2025.","Rule 14a-8 proposals also due Feb 23, 2025; submissions to Cambridge, MA office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183358,"accession_number":"0001493152-25-001704","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Eterna receives Nasdaq delisting notice for low MVLS; board changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.","Company has 180-day cure period (until July 7, 2025) to regain compliance with MVLS standard.","Director Dorothy Clarke resigned Jan 6, 2025; no disagreement with Company; remains general counsel.","Dr. Elena Ratner appointed to Board effective Jan 7, 2025; determined independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183357,"accession_number":"0001493152-25-000246","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received December 30, 2024: closing bid price below $1 for 30 consecutive business days.","Company has until June 30, 2025 to regain compliance for 10 consecutive business days.","If not cured, may request a second 180-day period if other listing standards are met.","Stock continues to trade on Nasdaq under symbol ERNA with no immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199950,"accession_number":"0001493152-24-042902","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","8.01","3.02","5.07","9.01"],"status":"ready","headline":"Eterna Therapeutics closes $1.1M private placement, exchanges debt for equity, addresses Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of shares for September 2024 transactions at Oct 29 annual meeting.","Closed private placement: issued 1,401,994 shares + 115,000 pre-funded warrants; gross proceeds $1.1M.","Exchange transactions: issued 38,302,029 shares for outstanding warrants and convertible notes.","Bridge notes converted: 6,244,237 shares + 1,764,000 pre-funded warrants; $0.50 conversion price.","Post-closing cap: ~51.4M shares outstanding; Nasdaq hearing on Nov 12 to address equity compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215959,"accession_number":"0001493152-24-038532","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Eterna Therapeutics enters exclusive license with Factor Bioscience for cancer, autoimmune, rare disease tech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license in cancer, autoimmune disorders, and rare diseases; replaces Nov 2023 and prior Exacis licenses.","Pays Factor $208,333/month for first 12 months and $50,000/month for first 9 months for patent costs.","Initial term one year, auto-renews; Eterna may terminate for any reason with 90 days notice.","Factor to provide services and materials to facilitate development and scale-up at third-party facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215958,"accession_number":"0001493152-24-038129","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Eterna raises $3.9M via 12% notes; proposes debt/warrant exchange for 38.3M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $3.9M 12.0% senior convertible note private placement; net proceeds for general corporate purposes.","Agreed to sell 1,516,997 shares at $0.75/share for $1.1M in a separate common stock private placement.","Proposes to exchange outstanding convertible notes and warrants for ~38.3M shares, subject to stockholder approval.","Annual meeting postponed from Sept 27 to Oct 29, 2024; stockholder proposals due Oct 5.","Support agreements covering ~48% of outstanding shares commit to vote in favor of stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215957,"accession_number":"0001493152-24-037815","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna Therapeutics receives Nasdaq delisting notice for failure to regain compliance with equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).","Trading of ERNA common stock will be suspended on Sept 26, 2024 unless a hearing request is filed by Sept 24, 2024.","Company intends to timely request a hearing with Nasdaq's Hearings Panel to appeal the determination; a stay will be in effect pending decision.","Hearings typically scheduled 30-45 days after request; panel decision within 30 days of hearing; no assurance of success.","If appeal fails or no request, a Form 25-NSE will be filed, removing ERNA from Nasdaq listing and registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215956,"accession_number":"0001493152-24-033119","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Eterna Therapeutics sets 2024 annual meeting for Sept 27; proposal deadline Aug 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for September 27, 2024.","Stockholder proposals and nominations must be received by August 29, 2024.","Date is >30 days from 2023 annual meeting anniversary, triggering special notice timeline.","All notices must be directed to company's principal executive offices per bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253250,"accession_number":"0001140361-24-014809","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna Therapeutics receives Nasdaq delisting notice for stockholders' equity below $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $2.2M as of Dec 31, 2024, below the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).","Company must submit a compliance plan to Nasdaq by May 3, 2024.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","No immediate effect on listing; common stock continues trading under ERNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253249,"accession_number":"0001140361-24-008273","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eterna Therapeutics appoints Peter Cicala to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Feb 12, 2024, effective immediately; independent director under Nasdaq rules.","Serves on Audit, Compensation, and Nominating & Corporate Governance Committees.","Receives standard non-employee director compensation per 2023 proxy statement.","No material interest transactions or arrangements with other persons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253248,"accession_number":"0001140361-24-002915","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna receives Nasdaq non-compliance notice over board independence; has 45 days to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 17, 2024 for failing majority independent board and audit committee rules under Listing Rule 5605.","Triggered by appointment of Dorothy Clarke as GC and her resignation from board committees, plus Sanjeev Luther joining board.","Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.","No immediate effect on listing; common stock continues trading under symbol ERNA.","Company is evaluating director candidates to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270717,"accession_number":"0001140361-23-058648","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Eterna raises $9.2M convertible debt, CEO resigns, Sanjeev Luther appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $9.2M principal of 12% senior convertible notes; initial close of ~$7.8M on Dec. 15, remainder by Jan. 15, 2024.","Notes convertible at $1.9194/share; warrants for 9.58M shares at $1.43; 10.46M existing warrants repriced to $1.43.","CEO Matthew Angel resigns effective Dec. 31, 2023, no disagreement; succeeded by Sanjeev Luther as President and CEO on Jan. 1, 2024.","New CEO Luther: base salary $550K, signing bonus $75K, option for 1,685,218 shares, target bonus 50% of base.","James Bristol appointed Chairman of the Board effective Dec. 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270716,"accession_number":"0001140361-23-057648","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Eterna Therapeutics issues $1.5M promissory note to Charles Cherington due Jan 8, 2024 at 6%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $1,500,000; interest rate 6% per annum; matures January 8, 2024.","Promissory Note is a senior unsecured obligation; ranks equally with existing unsubordinated debt.","Proceeds received on December 8, 2023; use of proceeds not specified beyond general corporate purposes.","Customary events of default include payment failure, bankruptcy, material adverse effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270715,"accession_number":"0001140361-23-053659","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eterna Therapeutics expands license from Factor Bioscience, gains know-how and multi-tier sublicense rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended & Restated Exclusive License Agreement dated Nov 14, 2023 expands Eterna's rights to include necessary know-how and multi-tier sublicensing.","CEO Matthew Angel is co-founder, President, CEO and director of Factor's parent company, creating a related-party transaction.","Licensor's termination rights are reduced; technology transfer to Eterna is now included subject to use restrictions.","Original agreement was from Feb 20, 2023, amended July 12, 2023; this restatement replaces it entirely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270714,"accession_number":"0001140361-23-050682","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. James Bristol appointed to board of Eterna Therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. James Bristol appointed as director effective Oct 30, 2023; term until 2024 annual meeting.","Bristol appointed to Audit, Compensation, and Nominating/Corporate Governance Committees.","Board determined Bristol is independent under Nasdaq rules; no material transactions with the Company.","Standard non-employee director compensation and indemnification agreement to be entered into."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270713,"accession_number":"0001140361-23-047156","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["3.01","5.02","8.01"],"status":"ready","headline":"Eterna receives Nasdaq delisting notice for audit committee non-compliance; director Fiore resigns","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Eterna on Oct 3, 2023 that audit committee no longer meets minimum three-member/independence requirement after Binder and Wagner resignations.","Cure period: until earlier of next annual meeting or Aug 9, 2024; if meeting before Feb 5, 2024, compliance due by Feb 5, 2024.","Director Gregory Fiore resigned Oct 4, 2023; not due to any disagreement with the company.","Nasdaq closed prior deficiency on independent director/audit/comp committee rules following appointment of Dorothy Clarke on Aug 31 and Sep 26, 2023.","Company evaluating director candidates to regain compliance; listing continues under symbol ERNA on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287622,"accession_number":"0001140361-23-045249","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K/A","filed_at":"2023-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dorothy J. Clarke appointed to all three committees of Eterna Therapeutics Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dorothy J. Clarke appointed to Audit Committee, Compensation Committee, and Nominating and Governance Committee.","Appointment effective September 23, 2023; committee roles are immediate.","Clarke joined the Board on August 28, 2023, for term through 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287628,"accession_number":"0001140361-23-042061","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eterna Therapeutics appoints Dorothy J. Clarke as director effective August 28, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Clarke served as VP, Health Care Compliance R&D at Johnson & Johnson until November 2022.","Board determined Clarke is independent under Nasdaq rules; standard non-employee director comp applies.","No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287627,"accession_number":"0001140361-23-039073","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"CEO resigns, then reappointed; board resignations trigger Nasdaq non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CEO Dr. Angel resigned Aug 4 citing board's exclusion from business dev; rescinded Aug 8, reappointed Aug 9.","Directors Binder and Wagner resigned Aug 8; Board reduced to two members (Wexler, Fiore).","Nasdaq notified non-compliance with independent director, audit & compensation committee rules.","Company has 45 days to submit compliance plan; up to 180-day extension possible if plan accepted.","Company actively searching for new directors to fill vacancies and regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287626,"accession_number":"0001140361-23-037681","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eterna Therapeutics posts August 2023 investor presentation; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Item 7.01 furnished new investor presentation (Exhibit 99.1) with no specific financial results or corporate events.","Presentation available on company website; filing does not contain earnings, guidance, or operational updates.","No material changes, transactions, or forward-looking statements identified in the furnished exhibit.","Routine disclosure intended to update investor materials without new material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287625,"accession_number":"0001140361-23-034885","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Eterna Therapeutics issues $8.715M in 6% convertible notes and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $8,715,000, 6.0% Senior Convertible Notes due July 14, 2028; interest payable quarterly.","Warrants to purchase up to 6,094,392 shares at $2.61/share (200% of conversion shares); exercisable for 5 years.","Initial conversion price $2.86/share; notes subject to beneficial ownership conversion limitations (4.99%-19.99%).","Directors Brant Binder and Richard Wagner, and former directors, participated on same terms as other purchasers.","Net proceeds for general working capital; Registration Rights Agreement to be filed within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287624,"accession_number":"0001140361-23-034310","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eterna Therapeutics amends Factor license: adds veterinary use, $416k/mo fee from Sep 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment expands field of use to include veterinary uses; initial term extended to 5 years if $6M paid.","Sublicense royalty reduced from 30% to 20%; monthly maintenance fee of $416,667 starts Sep 2024.","Factor’s termination rights for non-sublicensed patents eliminated; CEO Matthew Angel is co-founder of Factor parent.","Amendment considered a related-party transaction due to CEO's role at Factor Bioscience Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287623,"accession_number":"0001140361-23-034072","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eterna Therapeutics appoints Binder and Wagner to Board; Singer and Cherington resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicholas Singer and Charles Cherington resigned from Board on July 6, 2023; resignations not due to any disagreement.","Board appointed Brant C. Binder (President, Bonito Biosciences) and Dr. Richard W. Wagner (CEO, Bonito Biosciences) to fill vacancies.","Both new directors are independent under SEC/Nasdaq rules; Binder qualifies as audit committee financial expert.","Binder and Wagner assigned to Audit, Compensation, and Nominating and Corporate Governance Committees.","New directors will participate in standard non-employee director compensation arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307870,"accession_number":"0001140361-23-030499","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eterna Therapeutics shareholders approve all four proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected five directors: Cherington, Angel, Fiore, Wexler, Singer — each received >2.68M votes for, ~770K broker non-votes.","Ratified Grant Thornton as auditor for FY 2023: 3.52M for, 23K against, 6K abstain.","Approved potential issuance of >20% of outstanding shares under Lincoln Park Capital purchase agreement: 2.75M for, 27K against.","Approved amendment to Restated 2020 Stock Incentive Plan, increasing reserved shares from 680,599 to 980,599: 2.62M for, 160K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307869,"accession_number":"0001140361-23-023068","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eterna Therapeutics appoints Sandra Gurrola as PFO; CFO Jackson resigns with $207,500 severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Jackson resigned as CFO effective May 4, 2023; receives $207,500 salary continuation for 6 months plus COBRA premiums.","Sandra Gurrola appointed as principal financial officer effective May 5, 2023; she was previously VP Finance.","Jackson forfeited 33,239 unvested stock options granted June 3, 2022.","Separation agreement includes general release, cooperation, and confidentiality provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307868,"accession_number":"0001140361-23-022489","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Eterna Therapeutics acquires Exacis Biotherapeutics' IP assets in stock-and-contingent deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Eterna issued 69,343 shares to Exacis at closing; shares subject to 12-month lockup.","Contingent milestone: if market cap hits $100M, additional $2M in shares; at $200M, another $2M in shares.","Eterna to pay Exacis 20% of sublicensing revenue received within 5 years, capped at $45M.","CEO Matthew Angel is co-founder of Factor Bioscience (Exacis parent); director Gregory Fiore is CEO of Exacis; deal approved by audit committee and disinterested directors.","Eterna assumes only post-closing liabilities under the purchased license; Exacis retains other liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307867,"accession_number":"0001140361-23-017671","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Eterna Therapeutics secures up to $10M equity line from Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park committed to buy up to $10M of common stock over 24 months at Company's discretion.","Company issued 73,659 shares as commitment fee; purchases subject to volume and price limits.","No upper limit on purchase price per share; Lincoln Park cannot short or hedge during term.","Sales limited to 19.99% of outstanding shares unless stock price exceeds $3.6094 or shareholder approval obtained.","Company may terminate agreement with one business day notice; no penalties or liquidated damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326808,"accession_number":"0001140361-23-012545","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Eterna Therapeutics posts FY2022 net loss $24.6M; licenses iPSC tech to Lineage, subleases BMS space","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2022 was $4.5M ($1.24 per share); full year net loss $24.6M ($8.06 per share).","Cash and restricted cash $15.5M as of Dec 31, 2022; $4.1M restricted for BMS sublease.","Entered income-generating license agreement with Lineage Cell Therapeutics for gene-edited iPSC lines for neurology indications.","Subleased 45,000 sq. ft. from BMS at Cambridge Crossing; BMS provides $8.6M for build-out.","Appointed Matt Angel, Ph.D. as permanent CEO and President (previously interim)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326807,"accession_number":"0001140361-23-008076","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Eterna enters exclusive license with Factor for patents; prior deal terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license under Factor's patents for human uses; term ends Nov 22, 2027, auto-renewed 2.5 years if Eterna receives $100M in sublicense fees.","Eterna pays Factor 20% of sublicense fees before expiration, 30% during renewal; CEO Matthew Angel is co-founder/CEO of Factor's parent (related party).","Prior license agreement (April 2021, amended Nov 2022) terminated and superseded by this new agreement on Feb 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326806,"accession_number":"0001140361-23-002909","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eterna Therapeutics CMO Dr. Roger Sidhu resigns effective Jan 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Roger Sidhu, Chief Medical Officer, resigned on Jan 20, 2023 with effective date Jan 31, 2023.","No replacement or interim CMO has been announced in the filing.","Departure is effective immediately at the end of January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326805,"accession_number":"0001140361-23-001223","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Eterna Therapeutics transfers Nasdaq listing to Capital Market, effective Jan 11, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Staff approved transfer from Global Market to Capital Market on Jan 9, 2023.","Common stock begins trading on Capital Market at open on Jan 11, 2023 under symbol ERNA.","Company voluntarily applied for transfer on Jan 2, 2023 (previously reported).","Capital Market has similar corporate governance requirements but different financial listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326804,"accession_number":"0001140361-23-000340","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["3.01","5.02","9.01"],"status":"ready","headline":"Eterna Therapeutics to transfer Nasdaq listing after equity shortfall; Dr. Angel appointed CEO","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $8.8M missed Nasdaq Global Market's $10M minimum; Board authorized transfer to Capital Market on Dec 29, 2022, applied Jan 2, 2023.","Dr. Matthew Angel appointed President & CEO effective Jan 1, 2023; base salary $350k, signing bonus $210,959, performance bonus of 2% of gross proceeds from licensing etc.","Option grant to increase Dr. Angel's total options to 5% of outstanding shares; 50% vested on Start Date, remainder over 36 months.","Related party: Factor Bioscience (64% owned by Angel) receives $5M initial fee under MSA; license amended, option with Exacis terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344534,"accession_number":"0001140361-22-044598","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Eterna Therapeutics terminates San Diego office lease; consolidates R&D to Cambridge, MA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered lease termination agreement for 5,193 sq ft office at 10355 Science Center Drive, San Diego.","Lease will terminate if Landlord re-lets premises by Jan 15, 2023; effective Feb 28, 2023.","Termination fee of $100,000 payable in two installments; otherwise lease expires June 2027.","Termination aligns with previously announced decision in Q2 2022 to consolidate R&D in Cambridge, MA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344533,"accession_number":"0001140361-22-044329","cik":748592,"company_name":"Ernexa Therapeutics Inc.","ticker":"ERNA","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eterna closes ~$7.7M private placement with insider participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 2,184,950 units at $3.53/unit on Dec 2, 2022, raising ~$7.7M.","Each unit consists of one share of common stock and two warrants exercisable at $3.28/share.","Warrants exercisable after 6 months, expire June 2, 2028; include 4.99%/9.99% beneficial ownership limit.","Chairman Cherington and director Singer participated on same terms as other investors.","Net proceeds to be used for general working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12992949.434820648,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-05T23:59:59+00:00|344533"}